



MOREPEN

The Joy Of Growing Together



API - Product List

Sr. No.	Product Name	Innovator Brand Name	Therapeutic Segment	DMF/ COS/ Technical Package Status
1.	Loratadine USP/EP/IP)	Claritin	Anti-Histaminic	USD MF, CEP, JDMF, TDMF, CNDMF, EDMF, CDMF
2.	Desloratadine (USP/EP/BP/ICH)	Clarinex	Anti-Histaminic	USD MF, EDMF, CEP, TDMF, IDL China
3.	Montelukast Sodium (USP/EP/ICH/JP/IP)	Singulair	Anti-Asthmatic	USD MF, CEP, EDMF, CDMF, KDMF, IDL China
4.	Atorvastatin Calcium Crystalline Trihydrate (USP/ EP/ BP/JP/IP)	Lipitor	Anti-Lipemic	USD MF, EDMF, CEP, TDMF, KDMF, CNDMF
5.	Atorvastatin Calcium Amorphous (USP/IH)	Lipitor	Anti-Lipemic	DMF
6.	Rosuvastatin Calcium Crystalline (USP/EP/ICH/IP)	Crestor	Anti-Lipemic	USD MF, CEP, EDMF, TDMF
7.	Rosuvastatin Calcium Amorphous (USP/EP/IP)	Crestor	Anti-Lipemic	USD MF, EDMF, CEP
8.	Fexofenadine Hydrochloride (USP/EP/JP/IP)	Allegra	Anti-Histaminic	USD MF, EDMF, CEP, TDMF, JDMF, CNDMF
9.	Olmesartan Medoxomil (USP/EP/JP/IP)	Benicar	Anti-Hypertensive	USD MF, CEP (U/Review) , CNDMF, EDMF
10.	Sitagliptin Phosphate Monohydrate (USP/EP/IP)	Januvia	Anti-Diabetic	USD MF, CEP, TDMF, CNDMF, EDMF
11.	Sitagliptin Phosphate Anhydrous (USP/ICH)	Januvia	Anti-Diabetic	USD MF, EDMF
12.	Saxagliptin Hydrochloride (ICH/IH)	Onglyza	Anti-Diabetic	USD MF, EDMF, TDMF
13.	Saxagliptin Hydrochloride Dihydrate (ICH)	Onglyza	Anti-Diabetic	USD MF , EDMF
14.	Linagliptin (ICH/IH)	Tradjenta	Anti-Diabetic	USD MF , EDMF
15.	Linagliptin Form C (ICH)	Tradjenta	Anti-Diabetic	USD MF , EDMF
16.	Dapagliflozin Amorphous (ICH/IH)	Farxiga	Anti-Diabetic	USD MF , EDMF
17.	Dapagliflozin Propanediol (ICH/IH)	Farxiga	Anti-Diabetic	USD MF, CNDMF, EDMF
18.	Empagliflozin (ICH/IH)	Jardiance	Anti-Diabetic	USD MF, CNDMF, EDMF, TDMF

Note: The above products are not for sale where the patents are applicable & still valid.

MOREPEN LABORATORIES LIMITED

Corp. Off.: 2nd Floor, Tower C, DLF CYBER PARK, Phase III, Udyog Vihar, Sector 20, Gurugram, Haryana 122016, India
 Telephone: 91-124-489 2000, Email: api@morepen.com
 Website: www.morepen.com



API - Product List

Sr. No.	Product Name	Innovator Brand Name	Therapeutic Segment	DMF/ COS/ Technical Package Status
19.	Ertugliflozin L-Pyroglytamate (ICH/IH)	Steglatro	Anti-Diabetic	USDMF, CNDMF, EDMF
20.	Apixaban (ICH/IH)	Eliquis	Anti-Coagulant	USDMF, EDMF
21.	Apixaban Amorphous (ICH)	Eliquis	Anti-Coagulant	USDMF
22.	Edoxaban Tosylate (ICH/IH)	Savaysa	Anti-Coagulant	USDMF, EDMF
23.	Rivaroxaban (ICH/EP/USP/IH)	Xarelto	Anti-Coagulant	USDMF, EDMF, CEP
24.	Vortioxetine Hydrobromide (ICH/IH)	Trintellix	Anti-Depressant	USDMF, EDMF
25.	Vonoprazan Fumarate (ICH/IH)	Takecab	Anti-Ulcerative	DMF, CNDMF

APIs Developed / Under Pilot Trials / Validation

Sr. No.	Product Name	Innovator Brand Name	Therapeutic Segment	DMF/ COS/ Technical Package Status
1.	Brexiprazole (ICH/IH)	Rexulti	Anti-Depressant	Technical Package
2.	Paliperidone Palmitate (ICH/IH)	Invega	Anti-Psychotic	Technical Package
3.	Tafamidis Meglumine (ICH/IH)	Vyndaqel	CNS Agent	Technical Package
4.	Tafamidis (ICH/IH)	Vyndaqel	CNS Agent	Technical Package
5.	Baricitinib	Olumiant	Anti-Arthritis (Rheumatoid)	Technical Package
6.	Tofacitinib Citrate	Xeljanz	Anti-Arthritis (Rheumatoid)	Technical Package
7.	Bempedoic Acid (ICH/IH)	Nexletol	Anti-Lipemic	Technical Package
8.	Vortioxetine Hydrobromide Route II	Trintellix and Brintellix	Anti-Psychotic	Technical Package
9.	Nintedanib Esylate	Ofev	For Treatment of Chronic Fibrosis	PDR Ready,
10.	Trelagliptin Succinate	Zafatek	Anti-Diabetic	PDR Ready,

Note: The above products are not for sale where the patents are applicable & still valid.

MOREPEN LABORATORIES LIMITED

Corp. Off.: 2nd Floor, Tower C, DLF CYBER PARK, Phase III, Udyog Vihar, Sector 20, Gurugram, Haryana 122016, India
 Telephone: 91-124-489 2000, Email: api@morepen.com
 Website: www.morepen.com

APIs Under Development

Sr. No.	Product Name	Innovator	Brand Name	Therapeutic Segment	Development Timelines (Calendar Year)
1.	Bilastine	Faes Farma	Bilaxten	Anti-Histaminic	Q4 2023
2.	Imeglimin Hydrochloride	Poxel SA / Merck Sante	Twymeeg	Anti-Diabetic	Q4 2023
3.	Ticagrelor	Astrazeneca	Brilinta	Antiplatelet (for prevention of stroke & heart attack)	Q3 2023
4.	Cladribine	Merck	Mavenclad	Relapsing Remitting multiple sclerosis	Q1 2025
5.	Macitentan	Actelion	Opsumit	For Treatment of Pulmonary Arterial Hypertension (PAH)	Q3 2024
6.	Vericiguat	Bayer	Verquvo	Systolic Heart Failure	Q3 2024
7.	Finerenone	Bayer	Kerendia	Chronic Kidney Disease	Q3 2025
8.	Cariprazine Hydrochloride	Allergan Sales LLC	Vraylar	Anti-Psychotic (For treatment of Schizophrenia)	Q1 2026
9.	Mavacamten	Bristol Myers Squibb	Camzyos	Cardiovascular (To treat abnormally thick heart muscle)	Q1 2026

Note: The above products are for R&D purpose only & not for commercial sale where the patents are applicable & still valid.

APIs Under R&D Evaluation

Sr. No.	Product Name	Innovator	Brand Name	Therapeutic Segment	Development Timelines
1.	Upadacitinib	AbbVie	Rinvoq	Anti-Arthritis (Rheumatoid & Psoriatic)	—
2.	Ibrutinib	Pharmacyclics	Imbruvica	Anti-Cancer (For Mantle Cell lymphoma)	—
3.	Enzalutamide	Pharmacyclics	Xtandi	Anti-Cancer (For Prostate Cancer)	—
4.	Abemaciclib	Eli Lilly	Verzenio	Anti-Cancer (For HER2- Breast Cancer)	—
5.	Palbociclib	Pfizer	Ibrance	Anti-Cancer (For Breast Cancer)	—
6.	Olaparib	Astrazeneca	Lynparza	Anti-Cancer (For Ovarian / Breast cancer)	—
7.	Axitinib	Pfizer	Inlyta	Anti-Cancer (For Metastatic Renal Cell Carcinoma)	—

Note: The above products are for R&D purpose only & not for commercial sale where the patents are applicable & still valid.

MOREPEN LABORATORIES LIMITED



INTERMEDIATE LIST

Sr. No.	Product Name	Chemical Name of Intermediate	Intermediate Code	CAS No.
1.	Loratadine	8-Chloro-10, 11-dihydro-4-aza-5H-dibenzo (a, d) cycloheptan-5-one	L7	31251-41-9
		11-(N-Methyl-4-piperidinyl)-8-chloro-11-hydroxy- 6, 11-dihydro-5H-benzo(5,6) cyclohepta (1,2-b) pyridine	L8	38089-93-9
		11-(N-Methyl-4-piperidinylidene)-8-chloro-6, 11-dihydro-5H-benzo(5,6)cyclohepta (1,2-b) pyridine	L9 / LH9	38092-89-6
2.	Atorvastatin Calcium	(4R-Cis)-1,1-Dimethylethyl-6-[2-[2-(4-Fluorophenyl)-5-(1-Isopropyl)-3-phenyl-4-[(Phenylamino)carbonyl]1H-pyrrol-1-yl]Ethyl]-2,2-Dimethyl-1,3-Dioxane-4-Acetate	AT-8	125971-95-1
3.	Montelukast Sodium	[(R)-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl]propyl] thio]methyl] cyclopropane acetic acid, Dicyclohexyl amine salt	MTN12 / MK12	158966-92-8
		[(R)-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl] thio]methyl] Cyclopropane acetic acid		
4.	Fexofenadine Hydrochloride	2-(4-(4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-1-oxobutyl)phenyl)-2,2-dimethylacetic acid methyl ester	D10	154477-55-1
5.	Linagliptin	1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine	LG02	853029-57-9
		8-[(3R)-3-Boc-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione	LG03	668273-75-4
6.	Dapagliflozin Propanediol	Methyl-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl] phenyl]-D-Glucopyranoside	DP02	461432-24-6
		(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-[4-chloro-3-(4-ethoxybenzyl)phenyl]tetrahydro-2H-pyran-3,4,5-triyl triacetate	DP04	461432-25-7
7.	Empagliflozin	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl] methyl] phenyl]-6-(acetoxymethyl) oxane-3,4,5- triyl triacetate	EG04	915095-99-7
8.	Apixaban	Ethyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidin-1-yl) phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate	AX04	1074365-84-6
9.	Vonoprazan Fumarate	5-(2-Fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-carbaldehyde	VP02	881677-11-8
		1-[5-(2-Fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Or 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-Pyrrole-3-methanamine	VP04	881681-00-1
10.	Vortioxetine Hydrobromide	2,4-Dimethyl-1-[[2-nitrophenyl]sulfonyl]benzene	VXT02	1610527-49-5
		2-[[2,4-Dimethylphenyl]sulfonyl]aniline	VXT03	1019453-85-0

Note: The above products are not for sale where the patents are applicable & still valid.

MOREPEN LABORATORIES LIMITED

Corp. Off.: 2nd Floor, Tower C, DLF CYBER PARK, Phase III, Udyog Vihar, Sector 20, Gurugram, Haryana 122016, India
 Telephone: 91-124-489 2000, Email: api@morepen.com
 Website: www.morepen.com